A Phase 2 Study Of Anlotinib Combined With Pemetrexed-Platinum (Pp) As Second-Line Treatment In Egfr-Positive Non-Small Cell Lung Cancer (Nsclc)
JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
Anlotinib, Second-line therapy, EGFR-mutant NSCLC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要